Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...